Influenza Diagnostics Market by Test type (Traditional (Rapid Influenza Detection Test, Viral Culture, DFA, Serology Test), Molecular (RT-PCR, NASBA, LAMP, SAMBA)), End user (Hospital, Clinic, Reference lab, POC, Home Care Agency) - Global Forecast to 2021

インフルエンザ検査の世界市場予測(~2021年):迅速インフルエンザ検出、ウイルス培養、直接免疫蛍光分析(DFA)、血清学的検査、分子診断

◆タイトル:Influenza Diagnostics Market by Test type (Traditional (Rapid Influenza Detection Test, Viral Culture, DFA, Serology Test), Molecular (RT-PCR, NASBA, LAMP, SAMBA)), End user (Hospital, Clinic, Reference lab, POC, Home Care Agency) - Global Forecast to 2021
◆商品コード:MAM-BT5027
◆調査・発行会社:MarketsandMarkets
◆発行日:2017年2月23日
◆ページ数:130
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、インフルエンザ検査の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、検査種類別分析、需要先別分析、地域別分析、インフルエンザ検査の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

The global influenza diagnostics market is expected to reach USD 767.4 million by 2021 from USD 508.0 million in 2016, at a CAGR of 8.6% from 2016 to 2021. On the basis of test type, the market is segmented into traditional and molecular diagnostic tests. The traditional diagnostic tests segment is further categorized into rapid influenza detection tests (RIDT), viral culture, direct fluorescent antibody (DFA) tests, and serological assays. In 2016, the RIDT segment is expected to account for the largest share of the traditional tests market owing to factors such as its user-friendliness, rapid generation of results, and easy interpretability. The molecular diagnostic tests segment is further divided into RT-PCR, nucleic acid sequence-based amplification (NASBA) tests, loop-mediated isothermal amplification-based assays (LAMP), and simple amplification-based assays (SAMBA). In 2016, the RT-PCR segment is expected to hold the largest share of the molecular diagnostic tests market due to its ability to detect and distinguish between influenza A and B viruses with high specificity.
On the basis of end user, the influenza diagnostics market is segmented into hospitals/clinical laboratories, reference laboratories, and other end users (point-of-care testing, home health agencies, and nursing homes). The hospitals/clinical laboratories end-user segment is expected to dominate the influenza diagnostics market in 2016. The large share of this segment can be attributed to the fact that most influenza disease diagnostic tests are carried out in hospitals and clinical laboratories, as these tests are highly complex in nature and require the use of specialized instruments.

On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, and RoW. In 2016, the European region is expected to account for the largest share of the market due to the rapidly increasing prevalence of influenza and rise in aging population in Europe.

The increasing prevalence of influenza, growth in research funding for influenza diagnostics, and rising demand for rapid and effective disease diagnosis and treatment are the key factors driving the growth of the global influenza diagnostics market.

Research Coverage:
This report studies the influenza diagnostics market based on test type, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions

Reasons to Buy the Report:
The report will enable both established firms and new entrants to gauge the pulse of the market and to help them make important strategic growth decisions.

The report provides insights on the following:
• Product Development/Innovation: Product portfolios of the top players in the influenza diagnostics market. Detailed insights on upcoming technologies, research and development activities, and new product launches in the insights on upcoming technologies market

• Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of the leading players in the influenza diagnostics market

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various influenza diagnostic tests across geographies

• Market Diversification: Exhaustive information about new products, recent developments, and investments in the influenza diagnostics market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.2.1 MARKETS COVERED 15
1.2.2 YEARS CONSIDERED IN THE REPORT 15
1.3 CURRENCY 16
1.4 LIMITATIONS 16
1.5 STAKEHOLDERS 16

2 RESEARCH METHODOLOGY 17
2.1 MARKET SIZE ESTIMATION 18
2.2 MARKET RANKING ANALYSIS 20
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 21
2.3.1 KEY DATA FROM SECONDARY SOURCES 22
2.3.2 KEY DATA FROM PRIMARY SOURCES 23
2.3.3 ASSUMPTIONS FOR THE STUDY 23

3 EXECUTIVE SUMMARY 24
3.1 INTRODUCTION 24
3.2 CONCLUSION 28

4 PREMIUM INSIGHTS 29
4.1 INFLUENZA DIAGNOSTICS: MARKET OVERVIEW 29
4.2 GEOGRAPHIC ANALYSIS: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE (2016) 30
4.3 MOLECULAR DIAGNOSTIC TESTS MARKET SIZE, BY TYPE, 2016 VS. 2021 (USD MILLION) 31
4.4 LIFE CYCLE ANALYSIS, BY REGION (2016) 31

5 MARKET OVERVIEW 32
5.1 INTRODUCTION 33
5.2 DRIVERS 34
5.2.1 INCREASING PREVALENCE OF INFLUENZA 34
5.2.2 GROWTH IN RESEARCH FUNDING FOR INFLUENZA DIAGNOSTICS 34
5.2.3 RISING DEMAND FOR FASTER DIAGNOSIS AND CONTROL OF INFLUENZA 34
5.3 RESTRAINTS 35
5.3.1 VARIABILITY IN SENSITIVITY AND SPECIFICITY AMONG INFLUENZA DIAGNOSTIC TESTS 35
5.3.2 STRINGENT REGULATORY FRAMEWORK 35
5.3.3 RISING HEALTHCARE COSTS LIMITING THE USAGE OF NOVEL INFLUENZA DIAGNOSTIC TECHNIQUES 35
5.4 OPPORTUNITIES 35
5.4.1 ADVANCEMENTS IN GENOMIC AND PROTEOMIC TECHNOLOGIES 35
5.4.2 SIGNIFICANT GROWTH PROSPECTS IN DEVELOPING COUNTRIES 36
5.5 CHALLENGE 36
5.5.1 DEARTH OF SKILLED PERSONNEL TO HANDLE ADVANCED INFLUENZA DIAGNOSTIC TOOLS 36
5.6 REGULATORY FRAMEWORK 36
5.6.1 NORTH AMERICA 36
5.6.2 EUROPE 37
5.6.3 ASIA-PACIFIC 37
5.6.3.1 India 37
5.6.3.2 China 37
5.6.3.3 Australia 38

6 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE 39
6.1 INTRODUCTION 40
6.2 TRADITIONAL DIAGNOSTIC TESTS 41
6.2.1 RAPID INFLUENZA DETECTION TESTS (RIDT) 43
6.2.2 VIRAL CULTURE 44
6.2.3 DIRECT FLUORESCENT ANTIBODY (DFA) TESTS 46
6.2.4 SEROLOGICAL ASSAYS 48
6.3 MOLECULAR DIAGNOSTIC TESTS 50
6.3.1 RT-PCR 52
6.3.2 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION (NASBA) TESTS 53
6.3.3 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAYS (LAMP) 55
6.3.4 SIMPLE AMPLIFICATION-BASED ASSAYS (SAMBA) 56
6.3.5 OTHER MOLECULAR DIAGNOSTIC TESTS 57

7 INFLUENZA DIAGNOSTICS MARKET, BY END USER 60
7.1 INTRODUCTION 61
7.2 HOSPITALS/CLINICAL LABORATORIES 61
7.3 REFERENCE LABORATORIES 63
7.4 OTHER END USERS 64

8 INFLUENZA DIAGNOSTICS MARKET, BY REGION 66
8.1 INTRODUCTION 67
8.2 PEST ANALYSIS 68
8.2.1 POLITICAL FACTORS 68
8.2.2 ECONOMIC FACTORS 68
8.2.3 SOCIOCULTURAL FACTORS 68
8.2.4 TECHNOLOGICAL FACTORS 69
8.3 EUROPE 70
8.3.1 GERMANY 73
8.3.2 U.K. 75
8.3.3 REST OF EUROPE 77
8.4 NORTH AMERICA 79
8.4.1 U.S. 82
8.4.2 CANADA 84
8.5 ASIA-PACIFIC 87
8.6 REST OF THE WORLD (ROW) 89

9 COMPETITIVE LANDSCAPE 92
9.1 OVERVIEW 92
9.2 LEADING PLAYERS IN THE INFLUENZA DIAGNOSTICS MARKET 93
9.3 COMPETITIVE SITUATION AND TRENDS 94
9.3.1 PRODUCT LAUNCHES AND APPROVALS 94
9.3.2 ACQUISITIONS 95
9.3.3 EXPANSIONS 96
9.3.4 COLLABORATIONS AND AGREEMENTS 97

10 COMPANY PROFILES 98
10.1 INTRODUCTION 98
(Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, Ratio Analysis, MnM View)*
10.2 F. HOFFMANN-LA ROCHE AG 99
10.3 BECTON, DICKINSON AND COMPANY 101
10.4 THERMO FISHER SCIENTIFIC INC. 103
10.5 ALERE INC. 105
10.6 DIASORIN S.P.A. 107
10.7 QUIDEL CORPORATION 109
10.8 MERIDIAN BIOSCIENCE, INC. 111
10.9 ANALYTIK JENA AG (A SUBSIDIARY OF ENDRESS+HAUSER AG) 112
10.10 LUMINEX CORPORATION 114
10.11 SA SCIENTIFIC, LTD. 116
*Details on Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

11 APPENDIX 117
11.1 INSIGHTS OF INDUSTRY EXPERTS 117
11.2 DISCUSSION GUIDE 118
11.3 OTHER DEVELOPMENTS 120
11.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 121
11.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 123
11.6 AVAILABLE CUSTOMIZATIONS 125
11.7 RELATED REPORTS 126
11.8 AUTHOR DETAILS 127

LIST OF TABLES

TABLE 1 GLOBAL INFLUENZA DIAGNOSTICS MARKET SUMMARY 24
TABLE 2 INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2014–2021 (USD MILLION) 40
TABLE 3 INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS,
BY TYPE, 2014–2021 (USD MILLION) 41
TABLE 4 INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS,
BY REGION, 2014–2021 (USD MILLION) 42
TABLE 5 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY COUNTRY, 2014–2021 (USD MILLION) 42
TABLE 6 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL
DIAGNOSTIC TESTS, BY COUNTRY, 2014–2021 (USD MILLION) 42
TABLE 7 INFLUENZA DIAGNOSTICS MARKET SIZE FOR RIDT, BY REGION,
2014–2021 (USD MILLION) 43
TABLE 8 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR RIDT,
BY COUNTRY, 2014–2021 (USD MILLION) 44
TABLE 9 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR RIDT, BY COUNTRY,
2014–2021 (USD MILLION) 44
TABLE 10 INFLUENZA DIAGNOSTICS MARKET SIZE FOR VIRAL CULTURE, BY REGION,
2014–2021 (USD MILLION) 45
TABLE 11 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR VIRAL CULTURE,
BY COUNTRY, 2014–2021 (USD MILLION) 45
TABLE 12 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR VIRAL CULTURE,
BY COUNTRY, 2014–2021 (USD MILLION) 46
TABLE 13 INFLUENZA DIAGNOSTICS MARKET SIZE FOR DFA TESTS, BY REGION,
2014–2021 (USD MILLION) 46
TABLE 14 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR DFA TESTS,
BY COUNTRY, 2014–2021 (USD MILLION) 47
TABLE 15 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR DFA TESTS, BY COUNTRY, 2014–2021 (USD MILLION) 47
TABLE 16 INFLUENZA DIAGNOSTICS MARKET SIZE FOR SEROLOGICAL ASSAYS, BY REGION, 2014–2021 (USD MILLION) 48
TABLE 17 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR SEROLOGICAL ASSAYS, BY COUNTRY, 2014–2021 (USD MILLION) 49
TABLE 18 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR SEROLOGICAL ASSAYS,
BY COUNTRY, 2014–2021 (USD MILLION) 49
TABLE 19 INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS,
BY TYPE, 2014–2021 (USD MILLION) 50
TABLE 20 INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR TESTS, BY REGION, 2014–2021 (USD MILLION) 51
TABLE 21 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR TESTS, BY COUNTRY, 2014–2021 (USD MILLION) 51
TABLE 22 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR TESTS,
BY COUNTRY, 2014–2021 (USD MILLION) 51
TABLE 23 INFLUENZA DIAGNOSTICS MARKET SIZE FOR RT-PCR, BY REGION,
2014–2021 (USD MILLION) 52
TABLE 24 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR RT-PCR,
BY COUNTRY, 2014–2021 (USD MILLION) 53
TABLE 25 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR RT-PCR,
BY COUNTRY, 2014–2021 (USD MILLION) 53
TABLE 26 INFLUENZA DIAGNOSTICS MARKET SIZE FOR NASBA, BY REGION,
2014–2021 (USD MILLION) 54
TABLE 27 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR NASBA,
BY COUNTRY, 2014–2021 (USD MILLION) 54
TABLE 28 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR NASBA, BY COUNTRY, 2014–2021 (USD MILLION) 54
TABLE 29 INFLUENZA DIAGNOSTICS MARKET SIZE FOR LAMP, BY REGION,
2014–2021 (USD MILLION) 55
TABLE 30 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR LAMP,
BY COUNTRY, 2014–2021 (USD MILLION) 55
TABLE 31 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR LAMP, BY COUNTRY,
2014–2021 (USD MILLION) 56
TABLE 32 INFLUENZA DIAGNOSTICS MARKET SIZE FOR SAMBA, BY REGION,
2014–2021 (USD MILLION) 56
TABLE 33 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR SAMBA,
BY COUNTRY, 2014–2021 (USD MILLION) 57
TABLE 34 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR SAMBA, BY COUNTRY, 2014–2021 (USD MILLION) 57
TABLE 35 INFLUENZA DIAGNOSTICS MARKET SIZE FOR OTHER MOLECULAR DIAGNOSTIC TESTS, BY REGION, 2014–2021 (USD MILLION) 58
TABLE 36 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR OTHER MOLECULAR DIAGNOSTIC TESTS, BY COUNTRY, 2014–2021 (USD MILLION) 58
TABLE 37 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR OTHER MOLECULAR DIAGNOSTIC TESTS, BY COUNTRY, 2014–2021 (USD MILLION) 59
TABLE 38 INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 61
TABLE 39 INFLUENZA DIAGNOSTICS MARKET SIZE FOR HOSPITALS/CLINICAL LABORATORIES, BY REGION, 2014–2021 (USD MILLION) 62
TABLE 40 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR HOSPITALS/CLINICAL LABORATORIES, BY COUNTRY, 2014–2021 (USD MILLION) 62
TABLE 41 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR HOSPITALS/CLINICAL LABORATORIES, BY COUNTRY, 2014–2021 (USD MILLION) 63
TABLE 42 INFLUENZA DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES,
BY REGION, 2014–2021 (USD MILLION) 63
TABLE 43 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY COUNTRY, 2014–2021 (USD MILLION) 64
TABLE 44 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY COUNTRY, 2014–2021 (USD MILLION) 64
TABLE 45 INFLUENZA DIAGNOSTICS MARKET SIZE FOR OTHER END USERS, BY REGION, 2014–2021 (USD MILLION) 65
TABLE 46 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR OTHER END USERS, BY COUNTRY, 2014–2021 (USD MILLION) 65
TABLE 47 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR OTHER END USERS,
BY COUNTRY, 2014–2021 (USD MILLION) 65
TABLE 48 GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION,
2014–2021 (USD MILLION) 69
TABLE 49 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY,
2014–2021 (USD MILLION) 69
TABLE 50 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY,
2014–2021 (USD MILLION) 70
TABLE 51 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE,
2014–2021 (USD MILLION) 72
TABLE 52 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL
DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 72
TABLE 53 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 72
TABLE 54 EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 73
TABLE 55 GERMANY: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE,
2014–2021 (USD MILLION) 73
TABLE 56 GERMANY: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 74
TABLE 57 GERMANY: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 74
TABLE 58 GERMANY: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 75
TABLE 59 U.K.: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE,
2014–2021 (USD MILLION) 75
TABLE 60 U.K.: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 76
TABLE 61 U.K.: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 76
TABLE 62 U.K.: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 77
TABLE 63 ROE: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE,
2014–2021 (USD BILLION) 77
TABLE 64 ROE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 78
TABLE 65 ROE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 78
TABLE 66 ROE: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 79
TABLE 67 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE,
2014–2021 (USD MILLION) 81
TABLE 68 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 81
TABLE 69 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 82
TABLE 70 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 82
TABLE 71 U.S.: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE,
2014–2021 (USD MILLION) 83
TABLE 72 U.S.: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 83
TABLE 73 U.S.: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 84
TABLE 74 U.S.: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 84
TABLE 75 CANADA: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE,
2014–2021 (USD MILLION) 85
TABLE 76 CANADA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 85
TABLE 77 CANADA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 86
TABLE 78 CANADA: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 86
TABLE 79 APAC: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE,
2014–2021 (USD BILLION) 87
TABLE 80 APAC: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 88
TABLE 81 APAC: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 88
TABLE 82 APAC: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 89
TABLE 83 ROW: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE,
2014–2021 (USD MILLION) 89
TABLE 84 ROW: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 90
TABLE 85 ROW: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014–2021 (USD MILLION) 90
TABLE 86 ROW: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 91
TABLE 87 RANK OF COMPANIES IN THE INFLUENZA DIAGNOSTICS MARKET, 2015 93
TABLE 88 PRODUCT LAUNCHES AND APPROVALS, 2014–2016 95
TABLE 89 ACQUISITIONS, 2014–2016 95
TABLE 90 EXPANSIONS, 2014–2016 96
TABLE 91 COLLABORATIONS AND AGREEMENTS, 2014–2016 97



LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 17
FIGURE 2 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 19
FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 19
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 20
FIGURE 5 DATA TRIANGULATION METHODOLOGY 21
FIGURE 6 INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE,
2016 VS. 2021 (USD MILLION) 25
FIGURE 7 TRADITIONAL DIAGNOSTIC TESTS MARKET SIZE, BY TYPE,
2016 VS. 2021 (USD MILLION) 25
FIGURE 8 MOLECULAR DIAGNOSTIC TESTS MARKET SIZE, BY TYPE,
2016 VS. 2021 (USD MILLION) 26
FIGURE 9 INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER,
2016 VS. 2021 (USD MILLION) 27
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE INFLUENZA DIAGNOSTICS MARKET 28
FIGURE 11 RISING PREVALENCE OF INFLUENZA ACROSS THE GLOBE TO DRIVE THE INFLUENZA DIAGNOSTICS MARKET 29
FIGURE 12 RAPID INFLUENZA DETECTION TESTS TO COMMAND THE LARGEST
MARKET SHARE IN 2016 30
FIGURE 13 RT-PCR TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD 31
FIGURE 14 ASIA-PACIFIC PRESENTS LUCRATIVE GROWTH OPPORTUNITIES FOR PLAYERS
IN THE GLOBAL INFLUENZA DIAGNOSTICS MARKET 31
FIGURE 15 INFLUENZA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 33
FIGURE 16 RIDT TO DOMINATE THE TRADITIONAL DIAGNOSTIC TESTS MARKET IN 2016 41
FIGURE 17 RT-PCR TO DOMINATE THE MOLECULAR DIAGNOSTIC TESTS MARKET IN 2016 50
FIGURE 18 HOSPITALS/CLINICAL LABORATORIES TO DOMINATE THE INFLUENZA DIAGNOSTICS END-USER MARKET IN 2016 61
FIGURE 19 GEOGRAPHIC SNAPSHOT: ASIA-PACIFIC TO BE THE FASTEST-GROWING REGION DURING THE FORECAST PERIOD 67
FIGURE 20 EUROPE: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT 71
FIGURE 21 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT 80
FIGURE 22 COMPANIES MAJORLY PURSUED THE STRATEGY OF PRODUCT LAUNCHES AND APPROVALS BETWEEN 2014 AND 2016 92
FIGURE 23 BATTLE FOR MARKET SHARE: PRODUCT LAUNCHES AND APPROVALS WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS IN INFLUENZA DIAGNOSTICS MARKET BETWEEN 2014 AND 2016 94
FIGURE 24 GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS (2015) 98
FIGURE 25 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2015) 99
FIGURE 26 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2016) 101
FIGURE 27 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2015) 103
FIGURE 28 ALERE INC.: COMPANY SNAPSHOT (2015) 105
FIGURE 29 DIASORIN S.P.A.: COMPANY SNAPSHOT (2015) 107
FIGURE 30 QUIDEL CORPORATION: COMPANY SNAPSHOT (2015) 109
FIGURE 31 MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT (2015) 111
FIGURE 32 ANALYTIK JENA AG: COMPANY SNAPSHOT (2014) 112
FIGURE 33 LUMINEX CORPORATION: COMPANY SNAPSHOT (2015) 114


【レポートのキーワード】

インフルエンザ検査、インフルエンザ診断、病院、迅速インフルエンザ検出、ウイルス培養、直接免疫蛍光分析(DFA)、血清学的検査、分子診断

★調査レポート[インフルエンザ検査の世界市場予測(~2021年):迅速インフルエンザ検出、ウイルス培養、直接免疫蛍光分析(DFA)、血清学的検査、分子診断] ( Influenza Diagnostics Market by Test type (Traditional (Rapid Influenza Detection Test, Viral Culture, DFA, Serology Test), Molecular (RT-PCR, NASBA, LAMP, SAMBA)), End user (Hospital, Clinic, Reference lab, POC, Home Care Agency) - Global Forecast to 2021 / MAM-BT5027) 販売に関する免責事項
[インフルエンザ検査の世界市場予測(~2021年):迅速インフルエンザ検出、ウイルス培養、直接免疫蛍光分析(DFA)、血清学的検査、分子診断] ( Influenza Diagnostics Market by Test type (Traditional (Rapid Influenza Detection Test, Viral Culture, DFA, Serology Test), Molecular (RT-PCR, NASBA, LAMP, SAMBA)), End user (Hospital, Clinic, Reference lab, POC, Home Care Agency) - Global Forecast to 2021 / MAM-BT5027) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆